General Principles - The purpose of the implementation rules is to establish a sound assessment and compensation management system for the board of directors and senior management of the company, improving corporate governance structure [2] - The Compensation and Assessment Committee is a specialized working body established by the board of directors and is accountable to the board [2] Composition of the Committee - The Compensation and Assessment Committee consists of three directors, with independent directors making up more than half [4] - The committee members are nominated by the chairman, more than half of the independent directors, or one-third of all directors, and elected by the board [4] - The committee has a convener (chairperson) who is an independent director, responsible for leading the committee's work [6] Responsibilities and Authority - The committee is responsible for formulating assessment standards for directors and senior management, reviewing compensation policies, and making recommendations to the board on various matters [6] - The committee's proposed compensation plans for directors must be approved by the board and submitted for shareholder approval before implementation [10] - The committee must conduct an annual review of the compensation decision-making process and report findings to the board [11] Decision-Making Procedures - The committee's working group is responsible for preparing materials related to compensation and assessment decisions [12] - The assessment process includes self-evaluation by directors and senior management, followed by performance evaluations conducted by the committee [13] Meeting Rules - Meetings of the committee are called as needed, with notifications sent three days in advance, unless urgent [10] - A quorum requires attendance from at least two-thirds of the committee members, and decisions must be approved by a majority [15] - Meeting records must be kept, and confidentiality obligations apply to all attendees [22][24] Supplementary Provisions - The rules take effect upon approval by the board and are subject to relevant national laws and regulations [26][27] - The board holds the authority to interpret these rules [28]

塞力斯医疗科技集团股份有限公司 董事会提名委员会实施细则 塞力斯医疗科技集团股份有限公司 第三章 职责权限 第七条 提名委员会负责拟定董事、高级管理人员的选择标准和程序，对董 事、高级管理人员及其任职资格进行遴选、审核，并就下列事项向董事会提出建 议： 董事会提名委员会实施细则 （2025 年 8 月） 第一章 总则 第一条 为规范塞力斯医疗科技集团股份有限公司（以下简称"公司"）领 导人员的产生,优化董事会和高级管理层的组成,完善公司治理结构,根据相关法 律法规及《塞力斯医疗科技集团股份有限公司章程》（以下简称"《公司章程》"） 的规定，特制定本细则。 第二条 董事会提名委员会是董事会设立的专门工作机构,对董事会负责。 第二章 人员组成 第三条 提名委员会成员由 3 名董事组成，独立董事应当过半数。 第四条 提名委员会委员由董事长、二分之一以上独立董事或者全体董事的 三分之一提名,并由董事会选举产生。 第五条 提名委员会设召集人（即主任委员）一名,由独立董事委员担任,负 责主持委员会工作；召集人在委员内选举,并报请董事会批准产生。 第六条 提名委员会任期与董事会任期一致,委员任期届满,可以连选连任。 期间如 ...

证券代码：603716 证券简称：塞力医疗 公告编号：2025-072 债券代码：113601 债券简称：塞力转债 塞力斯医疗科技集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 全体董事均亲自出席本次董事会； ? 无董事对本次董事会议案投反对/弃权票； ? 本次董事会全部议案已获通过。 一、董事会会议召开情况 塞力斯医疗科技集团股份有限公司（以下简称"公司"）2025 年 8 月 17 日 以邮件方式发送第五届董事会第二十次会议通知，会议于 2025 年 8 月 27 日在公 司 A 栋 C 会议室以现场和通讯相结合的方式召开。本次会议应到董事 8 人，实到 董事 8 人，会议由董事长温伟先生主持，公司全体监事和高级管理人员列席了会 议。 本次董事会经过了适当的通知程序，会议的召集、召开和表决程序符合《公 司法》等相关法律法规和《公司章程》的规定，会议及通过的决议合法有效。 二、董事会会议审议情况 本次会议审议并通过如下议案： 表决结果：有效表决票共 8 票，其中同意票为 8 票，反对票为 ...

证券代码：603716 证券简称：塞力医疗 公告编号：2025-073 债券代码：113601 债券简称：塞力转债 塞力斯医疗科技集团股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ? 本次监事会全部议案已获通过。 一、监事会会议召开情况 塞力斯医疗科技集团股份有限公司（以下简称"公司"）2025 年 8 月 17 日 以邮件方式发送第五届监事会第九次会议通知，会议于 2025 年 8 月 27 日在公司 A 栋 C 会议室以现场和通讯相结合的方式召开。本次会议应出席监事 3 人，实际 出席监事 3 人，会议由监事会主席陈德先生主持。会议的通知、召集、召开、表 决程序符合《公司法》及《公司章程》的相关规定。 二、监事会会议审议情况 本次会议审议并通过如下议案： （一）审议通过《关于公司 2025 年半年度报告及其摘要的议案》 监事会认为：公司 2025 年半年度报告及其摘要的编制和审议程序符合法律、 法规、《公司章程》和公司内部管理制度的各项规定，报告的内容和格式符合中 国证监会和上海证券交易所的各项规定；公司 ...

| 新股发行及今日交易提示 | 2025/8/29 | 星期五 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025/8/29 | 内地市场权益提示 | 类别 | 证券代码 | 证券简称 | 权益日期 | 最新公告链接 | | | http://www.cninfo.com.cn/new/disclosure/detail?stockCode=600399&announcementId=122456 | 要约收购 | 600399 | 抚顺特钢 | 要约申报期：2025年8月12日至2025年9月10日 | 7286&orgId=gssh0600399&announcementTime=2025 | -08-26 | https://www.cninfo.com.cn/new/disclosure/detail?stockCode=688110&announcementId=122450 | | 严重异常波动 | 688110 | 东芯股份 | 0705&orgId=nssc1000767&announcementTime=2 ...

Group 1: Shuoshi Biotech - Shuoshi Biotech reported a significant decline in net profit for the first half of 2025, with a net profit of 3.99 million yuan, down 86.35% year-on-year [1] - The company’s non-recurring net profit was -28.05 million yuan, a staggering decrease of 1219.78% year-on-year [1] - Eight senior executives voluntarily reduced their salaries by 5% to 50% to demonstrate solidarity during challenging times, indicating a need for innovation and market expansion to find new profit growth points [1] Group 2: BeiGene - BeiGene announced that the European Commission has approved its PD-1 monoclonal antibody, Tislelizumab, for use in neoadjuvant therapy for adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence [2] - This approval marks a significant step for the internationalization of domestic PD-1 therapies, benefiting patients in Europe [2] Group 3: Shenzhou Cell - Shenzhou Cell reported a revenue of 972 million yuan for the first half of 2025, a decrease of 25.5% year-on-year, with a net profit of -33.77 million yuan, down 126.87% [3] - The second quarter saw a revenue of 452 million yuan, a decline of 34.66% year-on-year, and a net profit of -97.54 million yuan, down 289.37% [3] - Despite the revenue and profit decline, the company is actively advancing its R&D pipeline and exploring international markets [3] Group 4: Sali Medical - Sali Medical reported a revenue of approximately 584 million yuan for the first half of 2025, a decrease of 40.2% year-on-year, with a net loss of approximately 56.12 million yuan [4] - The company’s revenue and gross profit declined due to the transfer of some subsidiaries and challenges in its transformation, compounded by slow accounts receivable collection and difficulties in business renewals [4] - The company needs to accelerate its transformation efforts to improve performance [4]

Group 1 - Shuoshi Biotech reported a significant decline in net profit for the first half of 2025, with a net profit of 3.99 million yuan, down 86.35% year-on-year, and a non-recurring net profit of -28.05 million yuan, down 1219.78% year-on-year [1] - Eight senior executives, including the honorary chairman and the chairman, voluntarily reduced their salaries by 5% to 50%, demonstrating a commitment to overcoming current challenges [1] - The company faces pressure from industry-wide price reductions and tax rate adjustments, leading to a decline in gross margin, necessitating a focus on innovation and market expansion for future growth [1] Group 2 - BeiGene announced that the European Commission has approved its PD-1 monoclonal antibody, Tislelizumab, for use in neoadjuvant therapy for adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence [2] - This approval marks a significant step for the internationalization of domestic PD-1 therapies, benefiting patients in Europe [2] Group 3 - Shenzhou Cell reported a revenue of 972 million yuan for the first half of 2025, a decrease of 25.5% year-on-year, with a net profit of -33.77 million yuan, down 126.87% year-on-year [3] - The second quarter saw a revenue of 452 million yuan, down 34.66% year-on-year, and a net profit of -97.54 million yuan, down 289.37% year-on-year [3] - Despite the revenue decline, the company is actively advancing its R&D pipeline and exploring international markets, indicating potential for future growth [3] Group 4 - Sali Medical reported a revenue of approximately 584 million yuan for the first half of 2025, a decrease of 40.2% year-on-year, with a net loss of approximately 56.12 million yuan [4] - The company experienced a significant increase in net loss compared to the previous year, where the net loss was approximately 477,000 yuan [4] - Challenges include slow accounts receivable collection and difficulties in business renewals, necessitating a faster transformation to improve performance [4]

每经AI快讯，塞力医疗（SH 603716，收盘价：33.1元）8月29日发布公告称，公司第五届第二十次董事 会会议于2025年8月27日在公司A栋C会议室以现场和通讯相结合的方式召开。会议审议了《关于公司 2025年半年度报告及其摘要的议案》等文件。 （记者 张喜威） 2024年1至12月份，塞力医疗的营业收入构成为：商业占比97.09%，工业占比2.91%。 每经头条（nbdtoutiao）——申请超2万份，已开出41家，加盟海底捞，你要准备多少钱？1000万元不算 多，真实"账单"公布 ...

证券日报网讯 8月28日晚间，塞力医疗发布公告称，2025年半年度公司实现营业收入583，500，840.55 元，同比下降40.20%；归属于上市公司股东的净利润为-56，119，215.09元。 （编辑 何成浩） ...

格隆汇8月28日丨塞力医疗(603716.SH)发布中报，2025上半年实现营业总收入5.84亿元，同比下降 40.2%；归属母公司股东净利润-5611.92万元，较上年同期亏损增加5134.67万元；基本每股收益为-0.29 元。 ...